AllRock Bio
AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-ROCK inhibitor for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with the asset licensed from Sanofi and advancing through a Phase 2a trial.
- Company typePrivate
- Founded2024
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AllRock Bio does
AllRock Bio is a privately held, clinical-stage biotechnology company founded in April 2024 and based in Natick, Massachusetts, focused on developing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). The company's lead product candidate, ROC-101, is a first-in-class, orally administered pan-Rho-associated protein kinase (pan-ROCK) inhibitor exclusively licensed from Sanofi that selectively and potently inhibits both ROCK1 and ROCK2 isoforms, producing anti-proliferative, anti-inflammatory, and anti-fibrotic effects. ROC-101 completed a Phase 1 trial in 92 healthy volunteers demonstrating safety, no hypotension up to 40 mg once-daily, dose-dependent target engagement, and greater than 20 times the exposure of fasudil, and is now being evaluated in the open-label Phase 2a ROCSTAR trial (NCT07175038) enrolling up to 30 PAH and 10 ILD-PH patients in combination with standard of care including sotatercept, with pulmonary vascular resistance at week 24 as the primary endpoint.
The company operates as a spin-out from JucaBio under a hub-and-spoke model and is led by a team of repeat biotech entrepreneurs, most notably CEO Catherine Pearce and CBO Justin Thompson, who previously built CinCor Pharma through its acquisition by AstraZeneca for up to $1.8 billion in early 2023. The broader executive bench, including the CMO, CTMO, CFO, and heads of clinical operations, regulatory, and quality, draws heavily from the same CinCor alumni network, supplemented by experienced operators from Merck, Alexion, Keros Therapeutics, and other biopharma organizations. AllRock closed a $50 million Series A in September 2025 co-led by Versant Ventures and Westlake BioPartners to fund Phase 2a development.
AllRock is pre-revenue and its business model is centered on advancing ROC-101 through clinical development to FDA approval, at which point it intends to commercialize through traditional pharmaceutical channels targeting pulmonologists and specialized treatment centers, including specialty pharmacies, hospital pharmacies, and specialty distributors. Pricing has not yet been determined and will be set at launch in line with US specialty pharmaceutical benchmarks for orphan or rare cardiopulmonary indications. The underlying revenue mechanic is prescription drug sales of a single oral small-molecule asset across two indications with significant unmet need: PAH (approximately 57% five-year survival despite 16 approved drugs) and ILD-PH (approximately 38% five-year survival with very limited treatment options).
AllRock Bio firmographics
Firmographics- Name
- AllRock Bio
- Legal name
- Allrock Bio, Inc.
- Website
- https://allrockbio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-ROCK inhibitor for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with the asset licensed from Sanofi and advancing through a Phase 2a trial.
- Ownership category
- akta.pro rank
AllRock Bio industry classification
Industry- Product category
- Pulmonary Hypertension Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industries
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where AllRock Bio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AllRock Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Revenue: Once approved, AllRock Bio will generate revenue through the sale of ROC-101 for the treatment of PAH and ILD-PH. As a clinical-stage biotechnology company developing a novel therapeutic, revenue will come from prescription drug sales through traditional pharmaceutical commercialization channels.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
AllRock Bio product offering
Product offeringCore offering
AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively targets both ROCK1 and ROCK2 isoforms. The company is advancing ROC-101 through Phase 2a clinical trials (ROCSTAR) for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (ILD-PH), with potential for once-daily oral dosing in combination with standard of care including sotatercept.
Product overview
AllRock Bio is a clinical-stage biotechnology company developing ROC-101 as its lead product candidate. ROC-101 is a first-in-class, oral pan-ROCK inhibitor being advanced through clinical development for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). The company operates as a spin-off from JucaBio, leveraging expertise from previous biotech ventures including CinCor Pharma (acquired by AstraZeneca for up to $1.8 billion in 2023).
Differentiator
Problem solved
Functional benefit
Products and services
- ROC-101 ROC-101 is a first-in-class, oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively and potently inhibits both ROCK1 and ROCK2 isoforms. It targets anti-proliferative, anti-inflammatory, and anti-fibrotic mechanisms for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), with favorable pharmacokinetics supporting once-daily dosing and no evidence of hypotension at doses up to 40mg.
Quantifiable outcome
- Phase 1 demonstrated ROC-101 was safe, well-tolerated at all doses tested up to 40mg once daily with no evidence of hypotension
- +2 more outcomes
Companies that use AllRock Bio
Customer profileSegments2 records
Ideal customer profiles2 records
AllRock Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AllRock Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- SanoficoreAllRock Bio exclusively licensed ROC-101 from Sanofi. The pan-ROCK inhibitor was acquired by AllRock to advance through Phase 2 clinical development for PAH and ILD-PH.
- JucaBiocoreJucaBio is the parent company and founder of AllRock Bio. JucaBio is a privately held, clinical-stage biopharmaceutical company built on the hub-and-spoke model that acquires high-quality, differentiated assets and builds agile NewCos. Leadership team members including Catherine Pearce and Justin Thompson co-founded JucaBio.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
AllRock Bio competitors and assessment
Company assessmentBroad incumbents
- Acceleron Pharma (a Merck company): Developed sotatercept (Winrevair), the new standard-of-care backbone in PAH that AllRock's ROC-101 is being combined with; the strategic anchor whose commercial trajectory directly drives ROC-101 adoption.
- United Therapeutics: Largest dedicated PAH franchise (Tyvaso, Remodulin, Orenitram); serves the same PAH specialists and treatment centers and sets the standard-of-care against which ROC-101 will be combined.
Direct peers
- Tenax Therapeutics: Late-stage PAH-focused biotech developing levosimendan (TNX-101, TNX-103); overlaps with AllRock on PAH patient population, clinical-stage risk profile, and specialty cardiology/pulmonology channels.
- Liquidia Corporation: Commercializes YUTREPIA (inhaled treprostinil) for PAH and PH-ILD; directly overlaps with AllRock's ILD-PH patient population and competes in the same specialty pharmacy channel.
- Insmed: Develops brensocatib and is expanding into pulmonary hypertension; a clinical-stage respiratory biotech pursuing similar specialty pulmonology channels and PAH/ILD indications.
- Keros Therapeutics: Develops cibotercept (KERO-006), an activin receptor type IIB ligand trap for PAH that mechanistically follows sotatercept; directly comparable as a late-stage PAH biologic competitor and potential combination partner for AllRock's add-on strategy.
- Aerovate Therapeutics: Developed inhaled imatinib for PH-ILD; direct precedent for a clinical-stage PAH/PH-ILD asset and a useful comparable for valuation and strategic outcomes in the indication.
- Gossamer Bio: Clinical-stage biopharmaceutical company developing seralutinib for PAH (TYvaso/LTyP-A studies); competes head-to-head with AllRock for the same PAH specialists and treatment paradigm, also targeting vascular remodeling.
Emerging players
- Pharmosa BioPharm: Develops L-arginine formulations for PAH; overlaps with AllRock on PAH mechanism innovation and represents another clinical-stage entrant in the broader PAH development landscape.
- Altavant Sciences: Clinical-stage company developing rodatristat ethyl and other assets for PAH and rare respiratory diseases; comparable as a small, indication-focused PAH biotech targeting similar specialist prescribers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
AllRock Bio social profiles
Digital presenceAllRock Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
AllRock Bio leadership team
Management profileNumber of profiles
Profiles10 records
AllRock Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AllRock Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AllRock Bio
What does AllRock Bio do?
AllRock Bio is a clinical-stage biotechnology company developing ROC-101, a first-in-class oral pan-Rho-associated protein kinase (ROCK) inhibitor that selectively targets both ROCK1 and ROCK2 isoforms. The company is advancing ROC-101 through Phase 2a clinical trials (ROCSTAR) for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (ILD-PH), with potential for once-daily oral dosing in combination with standard of care including sotatercept.
Is AllRock Bio a public or private company?
AllRock Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was AllRock Bio founded?
AllRock Bio was founded in 2024. It employs 11 to 50 people.
Where is AllRock Bio based?
AllRock Bio is headquartered in Boston, United States, in the North America region.
How does AllRock Bio make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are AllRock Bio's main competitors?
Broad incumbents on record are Acceleron Pharma (a Merck company) and United Therapeutics. Direct peers are Tenax Therapeutics, Liquidia Corporation, Insmed, Keros Therapeutics, Aerovate Therapeutics and Gossamer Bio. Emerging players are Pharmosa BioPharm and Altavant Sciences.
Does AllRock Bio have an API?
No public API is recorded for AllRock Bio.
What industry is AllRock Bio in?
AllRock Bio's product category is Pulmonary Hypertension Therapeutics. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.